Skip to contentM
Medifast Inc
M
MEDMedifast Inc Q1 2023 · 10-Q
Revenue$348.98M$348.98M−16.4% vs Q1 2022 Net Income$39.97M$39.97M−4.3% vs Q1 2022 EPS Diluted$3.67$3.67+2.2% vs Q1 2022 Gross Profit$246,390,000−18.5% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Medifast Inc · CIK 910329 · Engraved from SEC EDGAR
Operating Cash Flow$64,059,000+46.7% Free Cash Flowderived$61,944,000+52.3% Margins · derivedGross margin70.6%−1.8 pt vs Q1 2022
Operating margin15.3%+2.1 pt vs Q1 2022
Net margin11.5%+1.4 pt vs Q1 2022
ended Mar 31, 2023 · filed May 1, 2023 · 31 d after period end